We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Jupiter Wellness, Inc. (“Jupiter” or the “Company”) (NASDAQ: JUPW), in connection with the proposed merger of the Company with Next Frontier Pharmaceuticals, Inc. (“Next Frontier Pharmaceuticals”).  Under the terms of the merger agreement, Next Frontier Pharmaceuticals’ stockholders will be entitled to receive convertible stock of Jupiter Wellness that is convertible into 65,000,000, shares of Jupiter Wellness common stock at the closing of the transaction. Such shares will be subject to a six-month standard lock-up agreement.

WeissLaw LLP is investigating whether (i) Jupiter’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, and (ii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.